International Journal of Infectious Diseases (Nov 2018)

HACEK infective endocarditis: Epidemiology, clinical features, and outcome: A case–control study

  • Juan Ambrosioni,
  • Clara Martinez-Garcia,
  • Jaume Llopis,
  • Cristina Garcia-de-la-Maria,
  • Marta Hernández-Meneses,
  • Adrián Tellez,
  • Carles Falces,
  • Manel Almela,
  • Bàrbara Vidal,
  • Elena Sandoval,
  • David Fuster,
  • Eduard Quintana,
  • José M. Tolosana,
  • Francesc Marco,
  • Asunción Moreno,
  • José M. Miró

Journal volume & issue
Vol. 76
pp. 120 – 125

Abstract

Read online

Objectives: The study aimed to describe the epidemiological, microbiological, and clinical features of a population sample of 17 patients with HACEK infective endocarditis (HACEK-IE) and to compare them with matched control patients with IE caused by viridans group streptococci (VGS-IE). Methods: Cases of definite (n = 14, 82.2%) and possible (n = 3, 17.6%) HACEK-IE included in the Infective Endocarditis Hospital Clinic of Barcelona (IE-HCB) database between 1979 and 2016 were identified and described. Furthermore, a retrospective case–control analysis was performed, matching each case to three control subjects with VGS-IE registered in the same database during the same time period. Results: Seventeen out of 1209 IE cases (1.3%, 95% confidence interval 0.69–1.91%) were due to HACEK group organisms. The most frequently isolated HACEK species were Aggregatibacter spp (n = 11, 64.7%). Intracardiac vegetations were present in 70.6% of cases. Left heart failure (LHF) was present in 29.4% of cases. Ten patients (58.8%) required in-hospital surgery and none died during hospitalization. In the case–control analysis, there was a trend towards larger vegetations in the HACEK-IE group (median (interquartile range) size 11.5 (10.0–20.0) mm vs. 9.0 (7.0–13.0) mm; p = 0.068). Clinical manifestations, echocardiographic findings, LHF rate, systemic emboli, and other complications were all comparable (p > 0.05). In-hospital surgery and mortality were similar in the two groups. One-year mortality was lower for HACEK-IE (1/17 vs. to 6/48; p = 0.006). Conclusions: HACEK-IE represented 1.3% of all IE cases. Clinical features and outcomes were comparable to those of the VGS-IE control group. Despite the trend towards a larger vegetation size, the embolic event rate was not higher and the 1-year mortality was significantly lower for HACEK-IE. Keywords: Endocarditis, HACEK, Viridans group streptococci, epidemiology, clinical characteristics, outcome, case-control